SIR-Spheres Y-90 resin microspheres
Sirtex Medical, Inc. · Decision date May 7, 2026
What did the FDA decide?
FDA records P990065/S019 as a supplement to PMA P990065, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 7, 2026.
FDA approval order statement
a process change to allow for an additional volume size (SIR-Y003, 0.6 GBq/1 mL) to the existing SIR-Spheres Y-90 resin microspheres product line
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Radiology
- Decision date
- May 7, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P990065/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Sirtex Medical, Inc.
- Product code
- NAW
- Decision code
- OK30
- Decision date
- May 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Microspheres radionuclide.
- Applicant
- Sirtex Medical, Inc.
- Product code
- NAW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P990065/S019 received
Application receipt date recorded by FDA.
P990065/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P990065. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NAW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TheraSphere Y-90 Glass Microspheres SystemP200029/S015 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 13, 2026 | FDA |
TheraSphereP200029/S014 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
TheraSphere Y-90 Glass Microspheres SystemP200029/S013 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jun 4, 2026 | FDA |
TheraSphereP200029/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 10, 2026 | FDA |
TheraSphereP200029/S011 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Feb 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sirtex Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801
Sources and methodology
- Original FDA record: P990065/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



